Association for Research in Otolaryngology

Sensorion Reports 2022 First Half Results

Retrieved on: 
목요일, 9월 22, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Adult, Presbycusis, Ototoxicity, POC, Platinum, CMC, Cisplatin, GLP, ODD, AAV, COMP, Control, FDA, Cochlea, Research, CIO, European Medicines Agency, GJB2, Thermo Fisher Scientific, European Commission, CTA, Company, Treasury, G7, Hearing loss, Perilymph, Huber loss, Partnership, Cancer, Chemistry, Patient, Clinical trial, CEO, The Association, Royal IHC, CDMO, Solution, G&A, Pasteur Institute, Committee, Association, Mali, Animal, EMA, OTOF, Association for Research in Otolaryngology, Pharmaceutical industry, Medical device, Dentistry, Vaccine, Fine chemical, Otorhinolaryngology

Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its half-year results as of June 30, 2022, alongside its outlook for the remainder of 2022.

Key Points: 
  • Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its half-year results as of June 30, 2022, alongside its outlook for the remainder of 2022.
  • Nawal Ouzren, CEO of Sensorion, said: Sensorion has made good progress across our pipeline of small molecule and gene therapy programs in the first half of this year.
  • In late 2021, Sensorion filed a proof-of-concept clinical trial application in CIO to evaluate the potential of SENS-401 treatment.
  • Following further analysis of the AUDIBLE-S study earlier in 2022, Sensorion has adapted the NOTOXIS trial design to focus SENS-401 in the prevention arm only.

Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021

Retrieved on: 
금요일, 2월 19, 2021
Biotechnology, Medical devices, Health, Genetics, Clinical trials, Health sciences, Health, Clinical research, Hearing loss, Association for Research in Otolaryngology, Drug discovery, Pharmaceutical industry, Food and Drug Administration, Sensorineural hearing loss, Clinical trial, Aro, Sensorion, ARO

This includes a poster on the preclinical evidence of its lead asset, SENS-401, supporting the therapeutic protocol used in the companys clinical trial on sudden sensorineural hearing loss (SSNHL).

Key Points: 
  • This includes a poster on the preclinical evidence of its lead asset, SENS-401, supporting the therapeutic protocol used in the companys clinical trial on sudden sensorineural hearing loss (SSNHL).
  • The poster on SENS-401 is one of three Sensorion presentations to be featured at the ARO MidWinter Meeting, which will take place on February 20-24, 2021.
  • The Association for Research in Otolaryngology (ARO) is the worlds largest organization of hearing and balance researchers both basic and clinical.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion.

Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

Retrieved on: 
수요일, 2월 17, 2021
Branches of biology, Medical specialties, Occupational safety and health, Otology, Tinnitus, Neurotology, Association for Research in Otolaryngology, Otorhinolaryngology

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc.(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 44th Annual MidWinter Meeting, to be held virtually February 20-24, 2021.

Key Points: 
  • SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc.(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 44th Annual MidWinter Meeting, to be held virtually February 20-24, 2021.
  • These include participation in an invited symposium, presentation of the previously disclosed positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss, and multiple presentations related to Otonomys preclinical programs.
  • We are pleased to have the opportunity to present clinical results for OTO-313 and OTO-413 during ARO, which is the premier meeting of research scientists in the neurotology field, said Alan Foster, Ph.D., Vice President, Research of Otonomy.
  • Additionally, our multiple presentations this year highlight the breadth of our pipeline and provide supportive data for our preclinical programs including OTO-825, a gene therapy for congenital hearing loss, and OTO-510, an otoprotectant for cisplatin-induced hearing loss.

Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

Retrieved on: 
목요일, 1월 23, 2020
Knowledge, Neuroscience, Neurotology, Otology, Otorhinolaryngology, Forward-looking statement, Association for Research in Otolaryngology, NASDAQ, Otic, Aro, Poster session, Articles

SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc.(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 43rd Annual MidWinter Meeting, to be held January 25-29, in San Jose, California.

Key Points: 
  • SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc.(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 43rd Annual MidWinter Meeting, to be held January 25-29, in San Jose, California.
  • All Otonomy presentations are during poster sessions occurring from 1 to 4 p.m. PST on the days indicated below.
  • The forward-looking statements in this press release are based on information available to Otonomy as of the date hereof.
  • Otonomy disclaims any obligation to update any forward-looking statements, except as required by law.

Decibel Therapeutics to Present at the Association for Research in Otolaryngology (ARO) Conference

Retrieved on: 
수요일, 2월 6, 2019
Health, Biotechnology, Genetics, Pharmaceutical, Association for Research in Otolaryngology

Decibel Therapeutics will showcase capabilities across its inner ear-focused drug discovery and development platform at the 42nd annual mid-winter meeting of the Association for Research in Otolaryngology (ARO) from February 9-13, 2019.

Key Points: 
  • Decibel Therapeutics will showcase capabilities across its inner ear-focused drug discovery and development platform at the 42nd annual mid-winter meeting of the Association for Research in Otolaryngology (ARO) from February 9-13, 2019.
  • This last year has been transformative for Decibel, said Michael Su, Ph.D., Decibels chief scientific officer.
  • Decibel Therapeutics, a clinical-stage biotechnology company, has established the worlds first comprehensive drug discovery, development, and translational research platform for hearing and balance disorders.
  • For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow @DecibelTx on Twitter.